Skip to content

News &
Events

news

25
September
2020
RemeGen Announces US FDA Has Granted Breakthrough Therapy Designation for Disitamab Vedotin (RC48) in Urothelial Cancer
23
September
2020
Expanded Access Policy for Investigational Product
3
August
2020
Expanded Access Policy for Investigational Product RC48
17
June
2020
RemeGen Co., Ltd. Announced New RC48-ADC Data in Patients with Advanced Gastric Cancer at ASCO
29
April
2020
RemeGen Announces US FDA Clearance of IND Application to Initiate Phase II Clinical Trial in Urothelial Cancer
Load more
For media inquiries, please contact Jennifer Gordon at
jgordon@spectrumscience.com